Trial Profile
Post-Marketing Surveillance on the Use of Prazaxa Capsules in Japanese Patients With Nonvalvular Atrial Fibrillation After the Availability of Idarucizumab
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 12 Apr 2022
Price :
$35
*
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Embolism and thrombosis; Stroke
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 12 Jan 2021 Status changed from active, no longer recruiting to completed.
- 07 Dec 2020 Planned primary completion date changed from 20 Nov 2020 to 22 Dec 2020.
- 07 Aug 2020 Planned End Date changed from 30 Sep 2020 to 29 Dec 2020.